(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Stitch Fix Reports Q3 Beat, LianBio's Infigratinib Gets Breakthrough Therapy Designation in China for Gastric Cancer

  • June 06th, 2023
  • 602 views

Stitch Fix, Inc. (Nasdaq: SFIX), an online personal styling service, reported a third-quarter fiscal 2023 loss of $0.19 per share, beating the consensus estimate of a loss of $0.30 per share. The company also exceeded its adjusted EBITDA guidance by delivering $10.1 million, leading to a significant expansion of its free cash flow. 

Looking ahead to the fourth quarter of fiscal 2023, Stitch Fix expecs net revenue in the range of $365 million to $375 million, slightly below the consensus estimate of $379.41 million. 

In after-hours, $SFIX was trading at $3.84, reflecting a positive movement of $0.16 (+4.34%).

LianBio (Nasdaq: LIAN), a biopharmaceutical company, recently announced positive topline results from a Phase 2a proof of concept trial evaluating infigratinib in Chinese patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma, specifically targeting fibroblast growth factor receptor-2 (FGFR2) gene amplification. 

The trial data suggest that infigratinib has the potential to offer meaningful clinical benefits in third-line or later gastric cancer. As a result, the China National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation to infigratinib for the treatment of gastric cancer, aiming to expedite its development and review process. 

Following this announcement, $LIAN was trading at $2.76, up $0.20 (+7.81%) in after-hours.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13